Login to Your Account



Alba Inks Ex-US/Japan Deal With Shire For Celiac Drug

By Trista Morrison


Monday, December 17, 2007
In a deal potentially worth more than $325 million, Shire plc picked up commercialization rights outside the U.S. and Japan for Alba Therapeutics Corp.'s gastrointestinal permeability inhibitor AT-1001. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription